Table 1.
Patient Characteristics
| Characteristics | N = 173 (%) |
|---|---|
| Age | |
| Median [Range], years | 56 [17–75] |
| ≤65 years | 138 (80%) |
| >65 years | 35 (20%) |
| Patient gender | |
| Male | 92 (53%) |
| Female | 81 (47%) |
| Karnofsky Score | |
| 90–100 | 85 (49%) |
| <90 | 56 (32%) |
| <80 | 25 (14%) |
| Missing | 7 (4%) |
| Sorror Score | |
| 0 | 29 (17%) |
| 1–2 | 78 (45%) |
| >2 | 64 (37%) |
| Missing | 2 (1%) |
| AML type | |
| De novo | 106 (61%) |
| Secondary | 52 (30%) |
| Therapy-related | 15 (9%) |
| Treatment status prior HCT conditioning | |
| 1st line | 110 (64%) |
| 1x Induction therapy | 35 (20%) |
| 2x Induction therapy | 22 (13%) |
| 1x IT and 1x consolidation | 53 (31%) |
| Relapse | 63 (36%) |
| Bone marrow blast count prior HCT conditioning | |
| Median [Range], % | 10 [0–96] |
| Bone marrow cellularity (cytomorphology) | |
| Aplastic/Hypocellular | 112 (65%) |
| Normocellular | 20 (12%) |
| Hypercellular | 11 (6%) |
| Unknown/not done | 30 (17%) |
| ELN | |
| Low | 15 (9%) |
| Intermediate I | 47 (27%) |
| Intermediate II | 63 (36%) |
| High | 48 (28%) |
| FLT3 mutation (N=156) | |
| Positive | 30 (19%) |
| Negativ | 126 (81%) |
| NPM1 mutation (N=152) | |
| Positiv | 23 (15%) |
| Negativ | 129 (85%) |
Abbreviations: AML, acute myeloid leukemia; HCT, allogeneic hematopoietic cell transplantation; IT, induction chemotherapy; ELN, European Leukemia Net.